# PDGFR

3 EU-approved indications of 2 drugs need a PDGFR result, in 2 tumour types, most of them in myeloid/lymphoid neoplasms with eosinophilia and TK fusions and gastrointestinal stromal tumour.

## Approved indications by tumour

### Gastrointestinal stromal tumour

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Avapritinib](https://oncolabels.com/drugs/avapritinib) (Ayvakyt) | PDGFRA D842V | Monotherapy | Advanced | - |

### Myeloid/lymphoid neoplasms with eosinophilia and TK fusions

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Imatinib](https://oncolabels.com/drugs/imatinib) (Glivec) | PDGFR fusion | Monotherapy | Any line | - |
| [Imatinib](https://oncolabels.com/drugs/imatinib) (Glivec) | FIP1L1-PDGFRalpha rearrangement | Monotherapy | Advanced | - |

## Label wording

- **Avapritinib** (Ayvakyt), Gastrointestinal stromal tumour, advanced: “AYVAKYT is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/ayvakyt-epar-product-information_en.pdf)
- **Imatinib** (Glivec), Myeloid/lymphoid neoplasms with eosinophilia and TK fusions, any line: “adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf)
- **Imatinib** (Glivec), Myeloid/lymphoid neoplasms with eosinophilia and TK fusions, advanced: “adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/biomarkers/pdgfr